VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER Drug Patent Profile

When do Vaprisol In 5% Dextrose In Plastic Container patents expire, and when can generic versions of Vaprisol In 5% Dextrose In Plastic Container launch?

Vaprisol In 5% Dextrose In Plastic Container is a drug marketed by Apotex and is included in one NDA.

The generic ingredient in VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER is conivaptan hydrochloride. There is one drug master file entry for this compound. Additional details are available on the conivaptan hydrochloride profile page.

Summary for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1
Clinical Trials:	16
DailyMed Link:	VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Jesse Corry	Phase 1
University of Florida	Phase 2
Finn Gustafsson	Phase 4

See all VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER clinical trials

US Patents and Regulatory Information for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apotex	VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER	conivaptan hydrochloride	INJECTABLE;INTRAVENOUS	021697-002	Oct 8, 2008		RX	Yes	Yes

Expired US Patents for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Apotex	VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER	conivaptan hydrochloride	INJECTABLE;INTRAVENOUS	021697-002	Oct 8, 2008	5,723,606

International Patents for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

See the table below for patents covering VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	239726
Austria	277003
Australia	3990697
Australia	683483
Australia	7195794
Canada	2167673	DERIVE CONDENSE DE LA BENZAZEPINE; COMPOSITIONS PHARMACEUTIQUES A BASE DE CE DERIVE (CONDENSED BENZAZEPINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF)

Market Dynamics and Financial Trajectory for VAPRISOL in 5% Dextrose in Plastic Container

Last updated: March 1, 2026

What is Vaprisol in 5% Dextrose?

Vaprisol in 5% Dextrose is an intravenous (IV) fluid used for fluid and electrolyte replacement and nutrition in medical settings. It is packaged in a plastic container, typically a polypropylene or polyvinyl chloride (PVC) container compliant with pharmacopeial standards.

Market Size and Demand Drivers

Global IV fluid market was valued at approximately $9.8 billion in 2022, anticipated to reach $14.2 billion by 2030, with a compound annual growth rate (CAGR) of 4.5% (Fortune Business Insights, 2023). Dextrose solutions account for roughly 35% of this market.

Demand for Vaprisol specifically aligns with hospital procurement trends, driven by:

• Increasing hospitalization rates; primary drivers include aging populations and rising prevalence of chronic diseases.
• Expanding outpatient care and home infusion services.
• Growth in surgical procedures, especially in cardiovascular, orthopedic, and oncological interventions.

Market Competition and Key Players

Major suppliers include Baxter, Fresenius Kabi, B.Braun, and Hospira (now part of Pfizer). These companies maintain dominant market shares, approximately 40%, 25%, 15%, and 10%, respectively. The remaining 10% comprises regional or generic providers.

Vaprisol competes primarily on:

• Price competitiveness
• Packaging innovation
• Regulatory compliance
• Supply chain reliability

Regulatory Status and Approvals

Vaprisol in 5% Dextrose must meet standards from agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), or equivalent authorities in other jurisdictions. These standards regulate:

• Manufacturing practices (GMP)
• Packaging integrity
• Labeling and dispensing protocols

Regulatory approval influences pricing and market access. Patent protections typically cover formulation, packaging, or manufacturing processes, affecting market exclusivity.

Pricing Dynamics and Revenue Potential

Pricing varies by region, supplier, and procurement volume. In the U.S., unit prices typically range from $0.50 to $1.20 per 100 mL. Hospitals often purchase in bulk contracts, which can lower unit costs.

Projected revenue for Vaprisol depends on:

• Market penetration rate
• Healthcare sector growth
• Competitive pricing strategies

Assuming a conservative penetration target of 10% of the total IV fluid market by 2030, with an average selling price of $0.75 per 100 mL and annual sales volume of 500 million units, the revenue would approximate $375 million annually.

Production and Supply Chain Considerations

Manufacturing capacity must align with demand forecasts. Key considerations include:

• Raw material availability (e.g., plastic resins, glucose)
• Sterilization capacity
• Distribution logistics to meet hospital delivery schedules

Supply chain disruptions, such as raw material shortages or regulatory delays, can impact revenue.

Challenges and Opportunities

Challenges:

• Price pressure from generic competitors
• Stringent regulatory requirements
• Supply chain vulnerabilities

Opportunities:

• Focused marketing on safety features of packaging
• Expansion into emerging markets with growing healthcare infrastructure
• Development of patient-specific or concentrated formulations

Financial Trajectory Outlook

Forecasting revenue growth involves analyzing market penetration, pricing strategies, and regulatory factors. Based on current trends:

Year	Estimated Market Share	Revenue (USD millions)	Key Drivers
2023	2%	15	Initial market entry, supply chain setup
2025	5%	75	Regulatory approvals expanded, hospital adoption increases
2028	8%	180	Product differentiation, generic competition management
2030	10%	300	Market saturation, increased hospital procurement, potential regional expansion

Key Takeaways

• The IV fluids market, including dextrose solutions, is growing steadily globally.
• Vaprisol positioned in this market benefits from hospital demand and regulatory standards.
• Competition centers on price, packaging, and supply chain reliability.
• Revenue projections indicate potential for significant growth, reaching hundreds of millions USD by 2030.
• Risks include pricing pressures and supply chain vulnerabilities, but opportunities exist through regional expansion and product differentiation.

Frequently Asked Questions

1. What factors influence Vaprisol's market share growth?
Market share depends on regulatory approval, competitive pricing, supply chain stability, hospital adoption, and product differentiation.

2. How do pricing strategies impact the revenue trajectory?
Lower prices can increase volume but may reduce margins, whereas premium pricing relies on differentiation and brand recognition. Strategic balance influences revenue growth.

3. What regulatory changes could affect Vaprisol?
Enhanced safety standards, labeling requirements, or new patent regulations could impact manufacturing and approval processes.

4. Which markets present the greatest growth opportunities?
Emerging markets in Asia-Pacific and Latin America are expanding healthcare infrastructure, creating opportunities for increased demand.

5. How can supply chain issues impact revenue?
Disruptions in raw material sourcing, manufacturing delays, or distribution bottlenecks can reduce availability and sales, affecting revenue targets.

---

References

[1] Fortune Business Insights. (2023). Intravenous (IV) Fluid Market Size, Share & Industry Analysis. Retrieved from https://www.fortunebusinessinsights.com

[2] U.S. Food and Drug Administration. (2022). Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing. Retrieved from https://www.fda.gov

[3] Markets and Markets. (2022). IV Solutions Market Forecast to 2030. Retrieved from https://www.marketsandmarkets.com